In this article, a meta-analysis of 12 groups of PCOS patients taking MET suggested that: the use of MET in PCOS patients will cause a decrease in serum AMH levels, both obese (BMI ≥ 30 kg/m2) and non-obese (BMI < 30 kg/m2) patients can occur, which suggests that even patients who are not obese can use MET to reduce the level of AMH, reduce the inhibition of follicular development, and increase the chance of spontaneous ovulation. Here, AMH is linked to polycystic ovary syndrome.